# EXtended Therapy in Hepatitis C Genotype 3 Infected Patients

> **NCT01095445** · PHASE3 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 2 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)

## Key facts

- **NCT ID:** NCT01095445
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Unlikely to recruit the adequate number of patients within a reasonable timeline
- **Last updated:** 2011-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01095445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01095445, "EXtended Therapy in Hepatitis C Genotype 3 Infected Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01095445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*